Systemic inflammatory status is associated with increased platelet reactivity in the early period after acute coronary syndromes

Stefano Cornara, Gabriele Crimi, Alberto Somaschini, Marco Cattaneo, Dominick J Angiolillo, Tullio Palmerini, Stefano De Servi

Research output: Contribution to journalArticle

Abstract

Systemic inflammation measured by high-sensitivity C reactive protein (CPR) is associated with increased risk of major adverse cardiovascular events (MACE). Recent clinical trials targeting CPR showed a reduction in MACE after an acute coronary syndrome (ACS). Inflammation could be linked to high platelet reactivity (HPR), which is an independent predictor of MACE in patients with ACS. We aimed to evaluate the impact of 1-month C-reactive Protein (CRP) levels on HPR in patients enrolled in the GEPRESS study. We measured CRP and platelet reactivity index (PRI) at 30 days follow-up. PRI was assessed with vasodilator stimulated phosphoprotein (VASP) phosphorylation assay at the same timepoint. HPR was defined as PRI >50%. Of the 1042 patients included in the GEPRESS study, 756 (75%) had both VASP and CRP data at 30 days follow-up. HPR was found in 61 (49.1%) patients with CRP >1 mg/L and 233 (36.4%) patients with CRP ≤1 mg/L, p = 0.012. After adjustment for covariates, we found a direct gradient of effect between CRP and HPR; the inclusion of CRP significantly increased the discrimination of HPR regression model. This is the first study showing that residual HPR is more likely to occur in patients with CRP >1 mg/L at 1 month after non-ST elevation-ACS and this may contribute to the unfavorable outcome observed in such patients.

Original languageEnglish
Pages (from-to)528-530
Number of pages3
JournalPlatelets
Volume29
Issue number5
DOIs
Publication statusPublished - Jul 2018

Fingerprint

Acute Coronary Syndrome
C-Reactive Protein
Blood Platelets
Inflammation
Phosphorylation
Clinical Trials

Keywords

  • Acute Coronary Syndrome/diagnosis
  • Aged
  • Blood Platelets/metabolism
  • C-Reactive Protein/adverse effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Risk Factors
  • Systemic Inflammatory Response Syndrome/blood

Cite this

Systemic inflammatory status is associated with increased platelet reactivity in the early period after acute coronary syndromes. / Cornara, Stefano; Crimi, Gabriele; Somaschini, Alberto; Cattaneo, Marco; Angiolillo, Dominick J; Palmerini, Tullio; De Servi, Stefano.

In: Platelets, Vol. 29, No. 5, 07.2018, p. 528-530.

Research output: Contribution to journalArticle

Cornara, Stefano ; Crimi, Gabriele ; Somaschini, Alberto ; Cattaneo, Marco ; Angiolillo, Dominick J ; Palmerini, Tullio ; De Servi, Stefano. / Systemic inflammatory status is associated with increased platelet reactivity in the early period after acute coronary syndromes. In: Platelets. 2018 ; Vol. 29, No. 5. pp. 528-530.
@article{30b48218df144c5da42774d8ebac7583,
title = "Systemic inflammatory status is associated with increased platelet reactivity in the early period after acute coronary syndromes",
abstract = "Systemic inflammation measured by high-sensitivity C reactive protein (CPR) is associated with increased risk of major adverse cardiovascular events (MACE). Recent clinical trials targeting CPR showed a reduction in MACE after an acute coronary syndrome (ACS). Inflammation could be linked to high platelet reactivity (HPR), which is an independent predictor of MACE in patients with ACS. We aimed to evaluate the impact of 1-month C-reactive Protein (CRP) levels on HPR in patients enrolled in the GEPRESS study. We measured CRP and platelet reactivity index (PRI) at 30 days follow-up. PRI was assessed with vasodilator stimulated phosphoprotein (VASP) phosphorylation assay at the same timepoint. HPR was defined as PRI >50{\%}. Of the 1042 patients included in the GEPRESS study, 756 (75{\%}) had both VASP and CRP data at 30 days follow-up. HPR was found in 61 (49.1{\%}) patients with CRP >1 mg/L and 233 (36.4{\%}) patients with CRP ≤1 mg/L, p = 0.012. After adjustment for covariates, we found a direct gradient of effect between CRP and HPR; the inclusion of CRP significantly increased the discrimination of HPR regression model. This is the first study showing that residual HPR is more likely to occur in patients with CRP >1 mg/L at 1 month after non-ST elevation-ACS and this may contribute to the unfavorable outcome observed in such patients.",
keywords = "Acute Coronary Syndrome/diagnosis, Aged, Blood Platelets/metabolism, C-Reactive Protein/adverse effects, Female, Humans, Male, Middle Aged, Risk Factors, Systemic Inflammatory Response Syndrome/blood",
author = "Stefano Cornara and Gabriele Crimi and Alberto Somaschini and Marco Cattaneo and Angiolillo, {Dominick J} and Tullio Palmerini and {De Servi}, Stefano",
year = "2018",
month = "7",
doi = "10.1080/09537104.2018.1457782",
language = "English",
volume = "29",
pages = "528--530",
journal = "Platelets",
issn = "0953-7104",
publisher = "Taylor & Francis",
number = "5",

}

TY - JOUR

T1 - Systemic inflammatory status is associated with increased platelet reactivity in the early period after acute coronary syndromes

AU - Cornara, Stefano

AU - Crimi, Gabriele

AU - Somaschini, Alberto

AU - Cattaneo, Marco

AU - Angiolillo, Dominick J

AU - Palmerini, Tullio

AU - De Servi, Stefano

PY - 2018/7

Y1 - 2018/7

N2 - Systemic inflammation measured by high-sensitivity C reactive protein (CPR) is associated with increased risk of major adverse cardiovascular events (MACE). Recent clinical trials targeting CPR showed a reduction in MACE after an acute coronary syndrome (ACS). Inflammation could be linked to high platelet reactivity (HPR), which is an independent predictor of MACE in patients with ACS. We aimed to evaluate the impact of 1-month C-reactive Protein (CRP) levels on HPR in patients enrolled in the GEPRESS study. We measured CRP and platelet reactivity index (PRI) at 30 days follow-up. PRI was assessed with vasodilator stimulated phosphoprotein (VASP) phosphorylation assay at the same timepoint. HPR was defined as PRI >50%. Of the 1042 patients included in the GEPRESS study, 756 (75%) had both VASP and CRP data at 30 days follow-up. HPR was found in 61 (49.1%) patients with CRP >1 mg/L and 233 (36.4%) patients with CRP ≤1 mg/L, p = 0.012. After adjustment for covariates, we found a direct gradient of effect between CRP and HPR; the inclusion of CRP significantly increased the discrimination of HPR regression model. This is the first study showing that residual HPR is more likely to occur in patients with CRP >1 mg/L at 1 month after non-ST elevation-ACS and this may contribute to the unfavorable outcome observed in such patients.

AB - Systemic inflammation measured by high-sensitivity C reactive protein (CPR) is associated with increased risk of major adverse cardiovascular events (MACE). Recent clinical trials targeting CPR showed a reduction in MACE after an acute coronary syndrome (ACS). Inflammation could be linked to high platelet reactivity (HPR), which is an independent predictor of MACE in patients with ACS. We aimed to evaluate the impact of 1-month C-reactive Protein (CRP) levels on HPR in patients enrolled in the GEPRESS study. We measured CRP and platelet reactivity index (PRI) at 30 days follow-up. PRI was assessed with vasodilator stimulated phosphoprotein (VASP) phosphorylation assay at the same timepoint. HPR was defined as PRI >50%. Of the 1042 patients included in the GEPRESS study, 756 (75%) had both VASP and CRP data at 30 days follow-up. HPR was found in 61 (49.1%) patients with CRP >1 mg/L and 233 (36.4%) patients with CRP ≤1 mg/L, p = 0.012. After adjustment for covariates, we found a direct gradient of effect between CRP and HPR; the inclusion of CRP significantly increased the discrimination of HPR regression model. This is the first study showing that residual HPR is more likely to occur in patients with CRP >1 mg/L at 1 month after non-ST elevation-ACS and this may contribute to the unfavorable outcome observed in such patients.

KW - Acute Coronary Syndrome/diagnosis

KW - Aged

KW - Blood Platelets/metabolism

KW - C-Reactive Protein/adverse effects

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Risk Factors

KW - Systemic Inflammatory Response Syndrome/blood

U2 - 10.1080/09537104.2018.1457782

DO - 10.1080/09537104.2018.1457782

M3 - Article

C2 - 29617211

VL - 29

SP - 528

EP - 530

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 5

ER -